For Healthcare Providers

For Healthcare Professionals

Uribel^® combines analgesic, antispasmodic, and antiseptic therapy in a single, easy-dosing capsule form—to help relieve the pain, burning, and spasms of lower urinary tract disorders.

Not all urinary pain relievers treat multiple symptoms

Unlike single-agent analgesic therapies, Uribel is formulated with a combination of ingredients that treat more than just pain.

	BLUE¹	ORANGE²
Analgesic for pain relief
Anti-inflammatory
Antispasmodic
Antiseptic ingredients^*
Can be taken on an empty stomach
Reduced staining potential
Restrictions on length of treatment with antibiotics	Can be taken until symptoms resolve^†	Should not exceed 2 days

Uribel capsule not actual size.
^*Uribel does not replace antibiotic therapy prescribed by a physician.
^†Duration of treatment will vary by patient and condition.

Restore relief with Uribel

The ingredients in Uribel capsules are generally well tolerated. There is no restriction on the length of therapy.

Adverse reactions may include: rapid heartbeat, flushing, blurred vision, dizziness, drowsiness, difficult micturition, acute urinary retention, dry mouth, nausea and vomiting, shortness of breath, or trouble breathing.

Patient savings

A valuable savings card may help your patients receive a discount off the retail price of each Uribel prescription, to assist with co-pay or out-of-pocket expenses.^‡

^‡Subject to eligibility. Terms and conditions apply.

References

Uribel [package insert]. San Antonio, TX: Mission Pharmacal Company.
Phenazopyridine hydrochloride [package insert]. Alpharetta, GA: Acella Pharmaceuticals, LLC.

Important Safety Information

CONTRAINDICATIONS: Hypersensitivity to any of the ingredients is possible. Risk benefits should be carefully considered with certain medical conditions: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy).

WARNINGS: Do not exceed recommended dosage. If rapid pulse, dizziness or blurring of vision occurs discontinue use immediately.

PRECAUTIONS: Uribel should be used with caution in:

patients who are intolerant of belladonna alkaloids or salicylates.

patients with gastric ulcers. Delay in gastric emptying could complicate management.

pregnant women. It is not known whether Uribel causes fetal harm or can affect reproductive capacity. Only use if clearly needed.

nursing mothers. Only use if clearly needed as methenamine and hyoscyamine are excreted in breast milk.

patients who require prolonged use. There have been no studies to establish the safety of long-term use in humans or animal studies to evaluate carcinogenic potential.

infants and young children as they are especially susceptible to the toxic effects of belladonna alkaloids.

elderly patients as they may experience excitement, agitation, drowsiness or confusion.

ADVERSE REACTIONS: Adverse reactions associated with Uribel include: rapid heartbeat, flushing, blurred vision, dizziness, drowsiness, difficult micturition, acute urinary retention, dry mouth, nausea, vomiting, and shortness of breath or trouble breathing.

Serious allergic reactions to this drug are rare. Patients should be instructed to seek immediate medical attention if they experience symptoms of a serious allergic reaction, including itching, rash, severe dizziness, swelling or trouble breathing.

This medication can cause urine and sometimes stools to turn blue to blue-green. This effect is harmless and will subside after medication is stopped, however, patients should be advised.

DRUG INTERACTIONS: Because Uribel can alter gastrointestinal motility and gastric emptying, it may decrease the absorption of other oral medications such as:

urinary alkalizers

thiazide diuretics (may reduce the effectiveness of methenamine)

antimuscarinics (may intensify antimuscarinic effects of hyoscyamine)

antacids/antidiarrheals (may reduce absorption of hyoscyamine; may reduce effectiveness of methenamine)
Doses of these medications should be spaced 1 hour apart from doses of Uribel

antimyasthenics (concurrent use may further reduce intestinal motility)

ketoconazole (patients should be advised to take Uribel at least 2 hours after ketoconazole)

monoamine oxidase (MAO) inhibitors (may intensify antimuscarinic side effects)

opioids (may result in increased risk of severe constipation)

sulfonamides (may increase the danger of crystalluria)

Methylene blue inhibits a range of CYP isozymes in vitro (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4/5). Interactions may be more pronounced with narrow therapeutic margin drugs that are metabolized by one of these enzymes (e.g., digoxin, warfarin, phenytoin, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus and tacrolimus. The clinical relevance of these in vitro interactions is unknown.